Effects of Sirolimus on Anti-SARS-CoV-2 Vaccination in Patients With Lymphangioleiomyomatosis

Chest. 2024 Feb;165(2):303-306. doi: 10.1016/j.chest.2023.09.014. Epub 2023 Sep 20.

Authors

Tat'Yana Worthy¹, Amanda Jones¹, Bennett E Yang¹, Hiroko Ishiwata-Endo¹, Nishant Gupta², Joel Moss³

Affiliations

¹ Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD.
² Division of Pulmonary, Critical Care, and Sleep Medicine, University of Cincinnati, Cincinnati, OH.
³ Pulmonary Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD. Electronic address: mossj@nhlbi.nih.gov.

PMID: 37739031
PMCID: PMC11026172 (available on 2025-02-01)
DOI: 10.1016/j.chest.2023.09.014

No abstract available

MeSH terms

Antibiotics, Antineoplastic / adverse effects
COVID-19* / prevention & control
Humans
Lung
Lung Neoplasms* / drug therapy
Lymphangioleiomyomatosis* / drug therapy
Sirolimus / adverse effects

Substances

Sirolimus
Antibiotics, Antineoplastic